PHIO
Phio Pharmaceuticals Corp.
Key Financials
Net Income
$-8698000
↓ 21.7%
Operating Income
$-9220000
↓ 24.8%
Revenue
$0
↓ 100.0%
EPS (Diluted)
$-9.08
↓ 74.6%
Total Liabilities
$1.3M
↑ 32.0%
Cash & Equivalents
$21.0M
↑ 290.8%
Shareholders' Equity
$20.1M
↑ 326.6%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 8-K | 4/8/2026 | View on SEC |
| 424B5 | 4/8/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 10-K | 3/5/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
| 8-K | 2/18/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PHIO |
| Company Name | Phio Pharmaceuticals Corp. |
| CIK | 1533040 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (508) 767-3861 |